ITCIのニュース
Intra-Cellular Therapies Has My Attention 2022/11/30 15:28:48 The Street RealMoney
We have two price targets….ITCI
Analysts Predict An Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Spike? 2022/11/19 12:30:00 Stocks Register
Intra-Cellular Therapies Inc. (NASDAQ:ITCI) shares, rose in value on Friday, 11/18/22, with the stock price up by 2.63% to the previous day’s close as strong demand from buyers drove the stock to $51.94. Actively observing the price movement in the last trading, the stock closed the session at $50.61, falling within a range of $50.39 … Analysts Predict An Intra-Cellular Therapies Inc. (NASDAQ: ITCI) Spike? Read More »
Intra-Cellular Therapies Inc. (ITCI) is an excellent investment, but the stock is overvalued/undervalued right now 2022/11/11 14:16:00 US Post News
A share of Intra-Cellular Therapies Inc. (NASDAQ:ITCI) closed at $50.67 per share on Thursday, up from $50.01 day before. While Intra-Cellular Therapies Inc. has overperformed by 1.32%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, ITCI rose by 17.81%, with highs and lows ranging from $66.00 […]
Intra-Cellular Therapies to Participate at Two Upcoming Investor Conferences 2022/11/10 13:00:00 GlobeNewswire
NEW YORK, Nov. 10, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will participate at two upcoming investor conferences:
Intra-Cellular Therapies, Inc. (ITCI) Q3 2022 Earnings Call Transcript 2022/11/03 18:42:05 Seeking Alpha
Intra-Cellular Therapies, Inc. (NASDAQ:NASDAQ:ITCI) Q3 2022 Earnings Conference Call November 03, 2022, 08:30 ET Company Participants Juan Sanchez - VP, Corporate Communications & IR…
SILVERARC CAPITAL MANAGEMENT, LLC Buys 4, Sells 1 in 3rd Quarter 2022/10/29 03:00:05 GuruFocus
Related Stocks: ITCI , PSTX , PRTA , ALNY , VRAY ,
Intra-Cellular Therapies to Host Third Quarter 2022 Financial Results Conference Call and Webcast 2022/10/27 12:00:00 GlobeNewswire
NEW YORK, Oct. 27, 2022 (GLOBE NEWSWIRE) -- Intra-Cellular Therapies, Inc. (Nasdaq: ITCI), a biopharmaceutical company focused on the development and commercialization of therapeutics for central nervous system (CNS) disorders, today announced that it will host a conference call and live webcast discussion at 8:30 a.m. Eastern Time on Thursday, November 3, 2022, to provide a corporate update and discuss details of the Company''s financial results for the quarter ended September 30, 2022.
Intra-Cellular Therapies: What Lies Ahead (NASDAQ:ITCI) 2022/09/20 23:45:38 Seeking Alpha
Today, we circle back on mid-cap biopharma name Intra-Cellular Therapies, Inc. for the first time since 2020. Click here to read an investment analysis.
Looking Into Intra-Cellular Therapies''s Return On Capital Employed 2022/09/02 14:25:59 Benzinga
Intra-Cellular Therapies (NASDAQ: ITCI ) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro . However, earnings decreased 20.08%, resulting in a loss of $86.60 million. Intra-Cellular Therapies collected $35.00 million in revenue during Q1, but reported earnings showed a $72.12 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com
Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug 2022/08/22 16:07:09 Seeking Alpha
Goldman Sachs downgraded commercial-stage biopharma Intra-Cellular Therapies, Inc
Intra-Cellular Therapies: What Lies Ahead (NASDAQ:ITCI) 2022/09/20 23:45:38 Seeking Alpha
Today, we circle back on mid-cap biopharma name Intra-Cellular Therapies, Inc. for the first time since 2020. Click here to read an investment analysis.
Looking Into Intra-Cellular Therapies''s Return On Capital Employed 2022/09/02 14:25:59 Benzinga
Intra-Cellular Therapies (NASDAQ: ITCI ) brought in sales totaling $55.58 million during Q2 according to data provided by Benzinga Pro . However, earnings decreased 20.08%, resulting in a loss of $86.60 million. Intra-Cellular Therapies collected $35.00 million in revenue during Q1, but reported earnings showed a $72.12 million loss. What Is Return On Capital Employed? Return on Capital Employed is a measure of yearly pre-tax profit relative to capital employed by a business. Changes in earnings and sales indicate shifts in a company''s ROCE. A higher ROCE is generally representative of successful growth of a company and is … Full story available on Benzinga.com
Intra-Cellular cut to Neutral at Goldman on trends for antipsychotic drug 2022/08/22 16:07:09 Seeking Alpha
Goldman Sachs downgraded commercial-stage biopharma Intra-Cellular Therapies, Inc
Goldman Sachs Downgrades Intra-Cellular Therapies to Neutral 2022/08/22 06:05:06 Investing.com
https://www.investing.com/news/pro/goldman-sachs-downgrades-intracellular-therapies-to-neutral-432SI-2877078
Director Of Intra-Cellular Therapies Makes $592K Sale 2022/08/15 14:45:34 Benzinga
Joel S Marcus , Director at Intra-Cellular Therapies (NASDAQ: ITCI ), reported a large insider sell on August 12, according to a new SEC filing. What Happened: A Form 4 filing from the U.S. Securities and Exchange Commission on Friday showed that Marcus sold 10,000 shares of Intra-Cellular Therapies . The total transaction amounted to $592,200. Intra-Cellular Therapies shares are trading down 3.77% at $51.55 at the time of this writing on Monday morning. Now trade stocks online commission free with Charles Schwab, a trusted and complete investment firm. The Importance of Insider Transactions Insider transactions shouldn''t be used primarily to … Full story available on Benzinga.com